A Clinical Trial of Thiabendazole in Strongyloidiasis

Branko Bezjak Hospital for Infectious Diseases, Zagreb, Yugoslavia

Search for other papers by Branko Bezjak in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary

A clinical trial of thiabendazole (Mintezol®, Merck, Sharp & Dohme) in the treatment of 30 cases of strongyloidiasis was done. Clinical, hematologic, and parasitologic criteria were used to determine the effectiveness of treatment. Twenty-nine patients were followed for up to 6 months; most were examined two or three times. In all patients, Strongyloides infection was eradicated by a single course of treatment, 25 mg per kilogram of body weight, twice daily on 2 successive days. In all but two patients, clinical symptoms diminished or disappeared. Eosinophilia demonstrated before treatment in 23 patients (mean eosinophil rate, 15.0%) persisted 6 months later in only three patients (mean rate, 7.0%).

Side-effects of the drug (most frequently, nausea) were recorded in 16 patients. In most instances all side-effects were mild and without much clinical significance.

Author Notes

Save